title: An ensemble prognostic model for colorectal cancer.
abstract: Colorectal cancer can be grouped into Dukes A, B, C, and D stages based on its developments. Generally speaking, more advanced patients have poorer prognosis. To integrate progression stage prediction systems with recurrence prediction systems, we proposed an ensemble prognostic model for colorectal cancer. In this model, each patient was assigned a most possible stage and a most possible recurrence status. If a patient was predicted to be recurrence patient in advanced stage, he would be classified into high risk group. The ensemble model considered both progression stages and recurrence status. High risk patients and low risk patients predicted by the ensemble model had a significant different disease free survival (log-rank test p-value, 0.0016) and disease specific survival (log-rank test p-value, 0.0041). The ensemble model can better distinguish the high risk and low risk patients than the stage prediction model and the recurrence prediction model alone. This method could be applied to the studies of other diseases and it could significantly improve the prediction performance by ensembling heterogeneous information.
authors: Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.
authors: Bi-Qing
authors: BQ
authors: Li
authors: Tao
authors: T
authors: Huang
authors: Jian
authors: J
authors: Zhang
authors: Ning
authors: N
authors: Zhang
authors: Guo-Hua
authors: GH
authors: Huang
authors: Lei
authors: L
authors: Liu
authors: Yu-Dong
authors: YD
authors: Cai
mesh_terms: D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D015233:Models, Statistical; D009367:Neoplasm Staging; D012008:Recurrence; D018570:Risk Assessment; D015996:Survival Rate
references: PLoS One. 2012;7(4):e33393
references: 22496748
references: Int J Ayurveda Res. 2010 Oct;1(4):274-8
references: 21455458
references: PLoS One. 2012;7(9):e45854
references: 23029276
references: Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2835-45
references: 18843029
references: Nat Rev Cancer. 2008 May;8(5):387-98
references: 18432252
references: PLoS One. 2009 Dec 02;4(12):e8126
references: 19956587
references: Oncol Rep. 2005 Jan;13(1):139-44
references: 15583815
references: Protein Pept Lett. 2013 Mar;20(3):352-63
references: 22591477
references: Mol Cancer. 2010 Jul 12;9:187
references: 20624318
references: J Clin Oncol. 2005 May 20;23(15):3526-35
references: 15908663
references: Int J Mol Med. 2002 Feb;9(2):107-12
references: 11786918
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Cell Cycle. 2009 Sep 1;8(17):2679-80
references: 19690460
references: Clin Cancer Res. 2011 Feb 15;17(4):647-53
references: 21159886
references: PLoS One. 2011;6(9):e25297
references: 21980418
references: Dokl Biochem Biophys. 2008 Mar-Apr;419:75-8
references: 18505162
references: Clin Cancer Res. 2009 Dec 15;15(24):7529-7537
references: 20008853
references: PLoS One. 2012;7(6):e39379
references: 22745744
references: PLoS One. 2009 Nov 02;4(11):e7715
references: 19888451
references: Ann Surg. 1954 Jun;139(6):846-52
references: 13159135
references: Mol Oncol. 2010 Apr;4(2):98-118
references: 20060370
references: J Cell Sci. 2005 Sep 1;118(Pt 17):3917-24
references: 16091420
references: Int J Mol Med. 2003 Nov;12(5):767-9
references: 14533007
references: Am J Pathol. 2009 Feb;174(2):613-29
references: 19164602
references: Curr Drug Targets. 2008 Jul;9(7):565-70
references: 18673242
references: Mol Cancer Res. 2011 Feb;9(2):133-48
references: 21228116
references: PLoS One. 2010 Apr 26;5(4):e10345
references: 20436681
references: Clin Cancer Res. 2009 Dec 15;15(24):7642-7651
references: 19996206
references: Gastroenterology. 2008 Jun;134(7):1869-81; quiz 2153-4
references: 18466904
references: PLoS One. 2012;7(6):e39308
references: 22720092
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D561-8
references: 21045058
references: Nature. 2012 Jul 18;487(7407):330-7
references: 22810696
references: Oncol Rep. 2004 May;11(5):957-63
references: 15069532
references: Biochem Biophys Res Commun. 2012 Jan 6;417(1):62-6
references: 22138402
references: Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1733-45
references: 17009964
references: Nature. 2005 Oct 20;437(7062):1173-8
references: 16189514
references: PLoS One. 2011;6(12):e28384
references: 22164281
references: Bioinformatics. 2003 Jan 22;19(2):185-93
references: 12538238
references: J Proteomics. 2012 Feb 16;75(5):1654-65
references: 22178444
references: Clin Cancer Res. 2011 Dec 15;17(24):7551-62
references: 21980136
references: IEEE Trans Pattern Anal Mach Intell. 2005 Aug;27(8):1226-38
references: 16119262
references: Mol Cell. 2009 May 14;34(4):497-509
references: 19481529
references: PLoS One. 2012;7(8):e43927
references: 22937126
references: Mol Biosyst. 2013 Jan 27;9(1):61-9
references: 23117653
references: PLoS One. 2010 Dec 22;5(12):e15737
references: 21203526
references: Science. 1997 Mar 21;275(5307):1784-7
references: 9065401
references: Mol Biosyst. 2012 Nov;8(11):2946-55
references: 22918520
references: PLoS One. 2010 Jun 30;5(6):e11404
references: 20614030
references: Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507
references: 17255271
references: Int J Cancer. 2009 Aug 15;125(4):861-7
references: 19437535